REG - Allergy Therapeutics - Appointment of Non-Executive Directors

Allergy TherapeuticsAnnouncement

06/12/2022 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20221206:nRSF7276Ia&default-theme=true

RNS Number : 7276I  Allergy Therapeutics PLC  06 December 2022

 

 

 

 

 

Allergy Therapeutics plc

("Allergy Therapeutics", the "Group" or "Company")

 

Appointment of Non-Executive Directors

 

6 DECEMBER 2022: Allergy Therapeutics plc (AIM: AGY), the fully integrated
commercial biotechnology company specialising in allergy vaccines, today
announces the appointments of Anthony Parker and Zheqing (Simon) Shen as
Non-Executive Directors of the Company, with immediate effect. Anthony
represents Southern Fox Investments Limited ("Southern Fox") and Simon
represents ZQ Capital Management Limited ("ZQ Capital") acting through its
affiliate SkyGem Acquisition Limited, both significant shareholders of the
Company.

 

Anthony has worked in investment banking and fund management for over thirty
years and, as Founder and Partner of Beagle Partners LLP, which advises
Southern Fox, has managed or advised on multiple UK innovation technology
investments. He is Founder and Chairman of Argonaute RNA Ltd, a UK-based
research company developing safe and reliable methods of temporarily silencing
target genes in different tissue cells. Prior to this, Anthony held senior
roles at ING Barings and was an equity analyst for Cazenove & Co. He holds
an Investment Management Certificate from the Institute of Investment
Management and Research.

 

Simon founded the investment and advisory firm, ZQ Capital, in 2015. Prior to
that he spent more than a decade as an investment banker advising
international companies on their capital markets activities. He was Managing
Director and Head of China Financial Institutions Group at Barclays from 2011
to 2015, following earlier roles at Goldman Sachs, Lehman Brothers and
McKinsey & Company. He has a BA in mathematics and economics from Wesleyan
University.

 

Peter Jensen, Non-Executive Chairman of Allergy Therapeutics, commented: "On
behalf of the Board I would like to welcome Anthony and Simon. Southern Fox
and ZQ Capital have been long-standing and supportive shareholders of Allergy
over many years, and I have no doubt Anthony and Simon will be invaluable
members of the Board, bringing extensive business and innovation sector
experience."

 

Additional Disclosures

 

The following information is disclosed pursuant to Rule 17 and Schedule Two
paragraph (g) of the AIM Rules of Companies.

 

Mr Anthony Michael Parker (aged 60) holds, or has held, the following current
and former directorships and partnerships in the past five years:

 

 Current Directorships and Partnerships  Former Directorships and Partnerships in the previous five years
 Argonaute RNA Limited
 Bristol Bluegreen Limited
 Beagle Partners LLP
 CBDerma Technology Limited
 Inverpharma Limited
 Las Lilas Limited

 

Mr Parker holds 275,000 ordinary shares in the capital of the Company. Mr
Parker does not hold any options, rights to subscribe or other interests in
such shares.

 

Mr Zheqing (Simon) Shen (aged 43) is, or has been, a director or partner of
the following companies or partnerships during the past five years:

 

 Current Directorships and Partnerships   Former Directorships and Partnerships in the previous five years
 ECC HK Holdings Limited                  ECC UK Holdings Limited
 Fortune Yacht Limited                    Innobeauty Global Limited
 KFM Kingdom Holdings Limited
 Nu Skin Enterprises, Inc.
 Ping An ZQ China Growth Opportunity Ltd
 Sky Venture Partners LP
 Skygem Acquisition Limited
 Skygem Global Limited
 Skygem International Holdings Limited
 Skygem Investment Limited
 Skygem UK Holding Limited
 ZQ Asset Management Limited
 ZQ Capital Hong Kong Holdings Ltd
 ZQ Capital Hong Kong Limited
 ZQ Capital Limited
 ZQ Capital Management Limited
 ZQ Capital Services Limited
 ZQ Evergreen Partners LP
 ZQ Partners Ltd
 ZQ Skygem Investors LP
 Z-Trans Technology Company Limited

 

Mr Shen holds 90,000 ordinary shares in the capital of the Company. In
addition, ZQ Capital, through its affiliate Skygem Acquisitions Limited holds
173,650,037 ordinary shares in the capital of the Company and also holds
warrants over 16,666,666 ordinary shares. Mr Shen is managing partner and
founder of ZQ Capital Mr Shen does not hold any other shares in the capital of
the Company, nor any options, rights to subscribe or other interests in such
shares.

 

Save as set out above, no further information regarding Anthony Parker or
Zheqing (Simon) Shen is required to be disclosed pursuant to Rule 17 and
Schedule Two paragraph (g) of the AIM Rules for Companies.

 

- ENDS -

 

 

For further information, please contact:

 

Allergy Therapeutics

+44 (0) 1903 845 820

Manuel Llobet, Chief Executive Officer

Martin Hopcroft, Interim Chief Financial Officer

 

Panmure Gordon (Nominated Adviser and Broker)

+44 (0) 20 7886 2500

Freddy Crossley, Emma Earl, Mark Rogers, Corporate Finance

Rupert Dearden, Corporate Broking

 

Consilium Strategic Communications

+44 20 3709 5700

Mary-Jane Elliott, David Daley, Davide Salvi

allergytherapeutics@consilium-comms.com
(mailto:allergytherapeutics@consilium-comms.com)

 

Stern Investor Relations, Inc.

+1 212 362 1200

Christina Tartaglia

christina@sternir.com (mailto:christina@sternir.com)

 

 

Notes for editors:

 

About Allergy Therapeutics

Allergy Therapeutics is an international commercial biotechnology company
focussed on the treatment and diagnosis of allergic disorders, including
aluminium free immunotherapy vaccines that have the potential to cure disease.
The Group sells proprietary and third-party products from its subsidiaries in
nine major European countries and via distribution agreements in an additional
ten countries. Its broad pipeline of products in clinical development includes
vaccines for grass, tree and house dust mite, and peanut allergy vaccine in
pre-clinical development. Adjuvant systems to boost performance of vaccines
outside allergy are also in development.

Formed in 1999 out of Smith Kline Beecham, Allergy Therapeutics is
headquartered in Worthing, UK with more than 11,000m(2) of state-of-the-art
MHRA-approved manufacturing facilities and laboratories. The Group employs
c.600 employees and is listed on the London Stock Exchange (AIM:AGY). For more
information, please see www.allergytherapeutics.com
(http://www.allergytherapeutics.com/)  .

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOAUPGRCPUPPUQQ